We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+5.02%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$650M
AUM Growth
+$95.3M
Cap. Flow
+$75.6M
Cap. Flow %
11.63%
Top 10 Hldgs %
57.73%
Holding
90
New
18
Increased
17
Reduced
23
Closed
25

Top Buys

Rank Stock Value
1
NPCE icon
Neuropace
NPCE
+$32.1M
2
FOCL
EDAP TMS S.A.
FOCL
+$16.9M
3
CCCC icon
C4 Therapeutics
CCCC
+$14.6M
4
NVCR icon
NovoCure
NVCR
+$14.3M
5
NEO icon
NeoGenomics
NEO
+$13.6M

Top Sells

Rank Stock Value
1
BCAB icon
BioAtla
BCAB
+$17.4M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$8.74M
3
KRYS icon
Krystal Biotech
KRYS
+$6.93M
4
DMRA
Damora Therapeutics, Inc. Ordinary Shares
DMRA
+$5.31M
5
FLXN
Flexion Therapeutics, Inc.
FLXN
+$4.68M

Sector Composition

Rank Sector Weight
1 Healthcare 90.8%
2 Consumer Staples 2.41%
3 Financials 0.49%
4 Real Estate 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
YMAB
26
DELISTED
Y-mAbs Therapeutics
YMAB
$4.88M 0.75%
+144,300
New +$4.63M
CMPS
27
Compass Pathways
CMPS
$1.53B
$4.87M 0.75%
127,743
+85,000
+199% +$3.04M
KRYS icon
28
Krystal Biotech
KRYS
$10.1B
$4.59M 0.71%
67,529
-99,315
-60% -$6.93M
ASMB icon
29
Assembly Biosciences
ASMB
$498M
$4.35M 0.67%
93,500
– –
XENE icon
30
Xenon Pharmaceuticals
XENE
$6.06B
$4.35M 0.67%
233,697
-474,420
-67% -$8.74M
INSP icon
31
Inspire Medical Systems
INSP
$1.45B
$4.17M 0.64%
+21,550
New +$4.27M
MDXG icon
32
MiMedx Group
MDXG
$602M
$4.03M 0.62%
322,160
-177,840
-36% -$1.93M
RVMD icon
33
Revolution Medicines
RVMD
$39.9B
$3.99M 0.61%
125,700
+68,500
+120% +$2.39M
CELC icon
34
Celcuity
CELC
$4.21B
$3.96M 0.61%
+164,824
New +$4.24M
LUNG icon
35
Pulmonx
LUNG
$68.8M
$3.76M 0.58%
+85,250
New +$3.71M
DYN icon
36
Dyne Therapeutics
DYN
$4.7B
$3.75M 0.58%
178,360
+4,000
+2% +$75.2K
AXGN icon
37
Axogen
AXGN
$2.27B
$3.42M 0.53%
+158,140
New +$3.2M
ARYD
38
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$3.22M 0.49%
300,000
– –
BEAM icon
39
Beam Therapeutics
BEAM
$2.63B
$2.84M 0.44%
+22,100
New +$1.76M
DMRA
40
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.78B
$2.72M 0.42%
21,526
-38,980
-64% -$5.31M
TKNO icon
41
Alpha Teknova
TKNO
$268M
$2.72M 0.42%
+114,546
New +$2.9M
CDNA icon
42
CareDx
CDNA
$2.26B
$2.68M 0.41%
+29,300
New +$2.33M
DXCM icon
43
DexCom
DXCM
$31.5B
$2.51M 0.39%
23,536
-4,204
-15% -$404K
PODD icon
44
Insulet
PODD
$11.5B
$2.46M 0.38%
+8,980
New +$2.44M
FDMT icon
45
4D Molecular Therapeutics
FDMT
$532M
$2.43M 0.37%
100,800
+14,700
+17% +$450K
ESTA icon
46
Establishment Labs
ESTA
$2.72B
$2.32M 0.36%
26,568
-34,583
-57% -$2.57M
MSON
47
DELISTED
Misonix Inc
MSON
$2.23M 0.34%
100,788
-200,545
-67% -$4.09M
GH icon
48
Guardant Health
GH
$21.7B
$2.17M 0.33%
+17,500
New +$2.35M
HALO icon
49
Halozyme
HALO
$9.79B
$2M 0.31%
+44,100
New +$1.95M
RFL icon
50
Rafael Holdings
RFL
$101M
$1.88M 0.29%
37,256
-49,580
-57% -$2.16M
1
2
3 4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return

Soleus Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Soleus Capital Management held 90 positions worth $650M, up 17% from $555M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Soleus Capital Management deployed $75.6M of net new capital in Q2 2021, opening 18 new positions and adding to 17 existing holdings. Its largest new stake was Neuropace: 1,384,387 shares worth $32.9M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was BioAtla, an estimated $17.4M trimmed.

  • Soleus Capital Management's largest Q2 2021 buy was Neuropace: 1,384,387 shares worth $32.9M.
  • Soleus Capital Management added most to EDAP TMS S.A. in Q2 2021, an estimated $16.9M increase.
  • Soleus Capital Management's biggest Q2 2021 reduction was BioAtla, cutting an estimated $17.4M.
  • Soleus Capital Management fully exited Flexion Therapeutics, Inc. in Q2 2021, selling an estimated $4.68M.
  • Soleus Capital Management's ten largest holdings make up 58% of its $650M portfolio in Q2 2021.
  • Soleus Capital Management opened 18 new positions and closed 25 in Q2 2021.
  • Soleus Capital Management's portfolio value rose 17% quarter-over-quarter to $650M.

Based on Soleus Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.